Literature DB >> 32611642

Evaluation of inflammatory lesions over 2 years in facioscapulohumeral muscular dystrophy.

Julia R Dahlqvist1, Nanna S Poulsen2, Sofie T Østergaard2, Freja Fornander2, Josefine de Stricker Borch2, Else R Danielsen2, Carsten Thomsen2, John Vissing2.   

Abstract

OBJECTIVE: We followed up patients with facioscapulohumeral muscular dystrophy (FSHD) with sequential examinations over 2 years to investigate whether inflammatory lesions always precede fat replacement, if inflammation can be resolved without muscle degeneration, and if inflammatory lesions in muscle are always followed by fat replacement.
METHODS: In this longitudinal study of 10 sequential MRI assessments over 2.5 years, we included 10 patients with FSHD. We used MRI with short TI inversion recovery to identify regions of interest (ROIs) with hyperintensities indicating muscle inflammation. Muscle T2 relaxation time mapping was used as a quantitative marker of muscle inflammation. Dixon sequences quantified muscle fat replacement. Ten healthy controls were examined with a magnetic resonance scan once for determination of normal values of T2 relaxation time.
RESULTS: We identified 68 ROIs with T2 elevation in the patients with FSHD. New ROIs with T2 elevation arising during the study had muscle fat content of 6.4% to 33.0% (n = 8) and 47.0% to 78.0% lesions that resolved (n = 6). ROIs with T2 elevation had a higher increase in muscle fat content from visits 1 to 10 (7.9 ± 7.9%) compared to ROIs with normal muscle T2 relaxation times (1.7 ± 2.6%; p < 0.0001). Severe T2 elevations were always followed by an accelerated replacement of muscle by fat.
CONCLUSIONS: Our results suggest that muscle inflammation starts in mildly affected muscles in FSHD, is related to a faster muscle degradation, and continues until the muscles are completely fat replaced. CLINICALTRIALSGOV IDENTIFIER: NCT02159612.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Year:  2020        PMID: 32611642     DOI: 10.1212/WNL.0000000000010155

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Elevated plasma complement components in facioscapulohumeral dystrophy.

Authors:  Chao-Jen Wong; Leo Wang; V Michael Holers; Ashley Frazer-Abel; Silvère M van der Maarel; Rabi Tawil; Jeffrey M Statland; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2022-06-04       Impact factor: 5.121

2.  Adapting MRI as a clinical outcome measure for a facioscapulohumeral muscular dystrophy trial of prednisone and tacrolimus: case report.

Authors:  Leo H Wang; Laura M Johnstone; Michael Bindschadler; Stephen J Tapscott; Seth D Friedman
Journal:  BMC Musculoskelet Disord       Date:  2021-01-09       Impact factor: 2.362

Review 3.  Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.

Authors:  Mehdi Ghasemi; Charles P Emerson; Lawrence J Hayward
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

4.  Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy.

Authors:  Leo H Wang; Dennis W W Shaw; Anna Faino; Christopher B Budech; Leann M Lewis; Jeffrey Statland; Katy Eichinger; Stephen J Tapscott; Rabi N Tawil; Seth D Friedman
Journal:  BMC Musculoskelet Disord       Date:  2021-03-10       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.